CRISPR Therapeutics 과거 수익 실적

과거 기준 확인 0/6

CRISPR Therapeutics의 수입은 연평균 -27%의 비율로 감소해 온 반면, Biotechs 산업은 수입이 연평균 7.7%의 비율로 증가했습니다. 매출은 연평균 7%의 비율로 감소해 왔습니다.

주요 정보

-27.0%

수익 성장률

-25.1%

EPS 성장률

Biotechs 산업 성장	18.9%
매출 성장률	-7.0%
자기자본 수익률	-12.4%
순이익	-118.1%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

CRISPR Therapeutics 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

BRSE:1CG 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
30 Sep 24	203	-240	71
30 Jun 24	202	-266	72
31 Mar 24	272	-217	72
31 Dec 23	371	-154	76
30 Sep 23	170	-354	81
30 Jun 23	170	-416	90
31 Mar 23	100	-524	97
31 Dec 22	1	-650	102
30 Sep 22	14	-681	105
30 Jun 22	15	-633	102
31 Mar 22	915	312	103
31 Dec 21	915	378	100
30 Sep 21	902	412	102
30 Jun 21	902	447	100
31 Mar 21	1	-392	93
31 Dec 20	1	-349	86
30 Sep 20	77	-211	80
30 Jun 20	289	20	74
31 Mar 20	289	46	68
31 Dec 19	290	67	63
30 Sep 19	213	-11	63
30 Jun 19	1	-200	57
31 Mar 19	2	-185	54
31 Dec 18	3	-165	48
30 Sep 18	35	-117	43
30 Jun 18	37	-91	41
31 Mar 18	40	-75	36
31 Dec 17	41	-68	36
30 Sep 17	11	-51	35
30 Jun 17	10	-41	31
31 Mar 17	7	-36	32
31 Dec 16	5	-23	31
30 Sep 16	3	-53	25
30 Jun 16	2	-44	24
31 Mar 16	1	-31	17
31 Dec 15	0	-26	13

양질의 수익: 1CG 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 1CG 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 1CG 은(는) 수익성이 없으며 지난 5년 동안 연간 27% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 1CG 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 1CG 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -18.2% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 1CG 현재 수익성이 없기 때문에 마이너스 자본 수익률( -12.35% )을 갖습니다.

CRISPR Therapeutics 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

Recent updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 23% undervalued

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기